ADC developer Tubulis expanded its Series C to $401 million to accelerate proprietary antibody‑drug conjugate programs, reflecting investor appetite for differentiated oncology platforms. Separately, European healthcare private equity firm GHO Capital closed Fund IV at €2.5 billion (~$2.9 billion), its largest raise to date, earmarked for investments across biopharma, medtech, life‑science tools and healthtech. Tubulis’s upsize provides runway to de-risk programs and push assets toward IND-enabling studies or clinical trials, while GHO’s fund signals sustained private capital deployment into healthcare despite market cycles. The PE fund plans a targeted number of platform investments, underscoring selective, scale-focused dealmaking. Together these financings illustrate that sizable capital is flowing into both early-stage science (ADC platforms) and buy-and-build strategies across healthcare verticals, shaping consolidation and innovation funding over the coming years.